Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Open Access
- 15 May 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (10) , 5109-5117
- https://doi.org/10.1182/blood-2007-05-091579
Abstract
The JAK2V617F mutation was found in most patients with myeloproliferative disorders (MPDs), including polycythemia vera, essential thrombocythemia, aKeywords
This publication has 31 references indexed in Scilit:
- Characterization of a Highly effective protein substrate for analysis of JAK2V617F ActivityExperimental Hematology, 2007
- In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 alleleExperimental Hematology, 2007
- Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell GrowthJournal of Biological Chemistry, 2007
- Polycythemia vera is not initiated by JAK2 mutationExperimental Hematology, 2007
- Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617FPLOS ONE, 2006
- The Myeloproliferative DisordersNew England Journal of Medicine, 2006
- JAK2V617F: prevalence in a large Chinese hospital populationBlood, 2006
- The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersBlood, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005